In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Y-Mabs Therapeutics Inc (YMAB). The company’s shares closed last Monday at $26.16.
According to TipRanks.com, Peaker is a 2-star analyst with an average return of 0.4% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Y-Mabs Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $40.
See today’s analyst top recommended stocks >>
Based on Y-Mabs Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.93 million. In comparison, last year the company had a GAAP net loss of $3.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
